title: Serum lipids and lipoproteins in continuous or cyclic medroxyprogesterone acetate treatment in postmenopausal women treated with conjugated estrogens.
abstract: This study evaluates effects on serum lipids of continuous or sequential progestogens for hormonal replacement in women. Subjects received either a cyclic regimen of replacement (0.625 mg/d of conjugated equine estrogens (Es) for 25 days/month and 10 mg medroxyprogesterone acetate [MPA] for the last 13 days of E) or 0.625 mg/d E along with either 5 or 10 mg MPA (Provera, Upjohn Company, Kalamazoo, MI). Study parameters were measured over a 24-week period. No differences in total cholesterol, high-density lipoprotein (HDL) cholesterol, triglycerides, apolipoproteins I and II, sex hormone-binding globulin, or serum MPA levels were noted between the sequential and 5 mg continuous group. The 10 mg MPA group did not have an increase in HDL or decrease in low-density lipoprotein as did the other groups.
authors.affiliation: Department of Obstetrics and Gynecology, Madigan Army Medical Center, Tacoma, Washington 98431-5454.
authors.forename: M K
authors.initials: MK
authors.lastname: Yancey
authors.forename: C J
authors.initials: CJ
authors.lastname: Hannan
authors.forename: S R
authors.initials: SR
authors.lastname: Plymate
authors.forename: I K
authors.initials: IK
authors.lastname: Stone
authors.forename: K E
authors.initials: KE
authors.lastname: Friedl
authors.forename: J R
authors.initials: JR
authors.lastname: Wright
mesh_terms: D000328:Adult; D000368:Aged; D004305:Dose-Response Relationship, Drug; D015914:Estrogen Replacement Therapy; D004967:Estrogens / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008055:Lipids / Q000097:blood*; D008074:Lipoproteins / Q000097:blood*; D008525:Medroxyprogesterone / Q000627:therapeutic use*; D008593:Menopause / Q000097:blood*; D008875:Middle Aged; D011446:Prospective Studies
chemical_list: D004967:Estrogens; D008055:Lipids; D008074:Lipoproteins; D008525:Medroxyprogesterone